Subscribe
shutterstock_547705978_fabio_berti
Fabio Berti / Shutterstock.com
26 October 2020AmericasSarah Morgan

Canada's drug pricing plan prompts backlash

The final version of guidelines issued by Canada’s federal drug price regulator last week has caused uproar among the pharma industry.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
Pricing, patents and the PMPRB in Canada
14 December 2020   Micheline Gravelle and Iris Cheung of Bereskin & Parr provide an update on the final version of guidelines issued by Canada’s federal drug price regulator—and its likely implications.
Big Pharma
Canada authorises compulsory licences for COVID-19 shortfalls
27 March 2020   Canada is the latest country to adopt emergency measures in order to secure drugs and medical equipment in the fight against COVID-19.
Americas
Pharma industry challenges Canada’s drug pricing plan
9 September 2019   Innovative Medicines Canada, an association that represents drugmakers in Canada, has challenged the overhaul of Canada’s drug-pricing regime.


Editor's picks

LSPN: In-house ‘chess game’ is the same, but the rules have changed
Americas
LSPN: In-house ‘chess game’ is the same, but the rules have changed
9 May 2025

Editor's picks

Americas
LSPN: In-house ‘chess game’ is the same, but the rules have changed
9 May 2025
Americas
LSPN: Counsel grapple with AI’s impact on training and critical thinking
8 May 2025
Americas
LSPN: Using ‘the patentee’s friend’ in Section 112 claims
6 May 2025
Americas
Why US patent reform is ‘essential’ for US economic prosperity and security
29 April 2025
Europe
Meril v Edwards: Harmonisation of obviousness at the UPC and the EPO
24 April 2025
Americas
WIPR Diversity & Inclusion reveals Top 100 People in IP for 2025
24 April 2025

More on this story

Big Pharma
Pricing, patents and the PMPRB in Canada
14 December 2020   Micheline Gravelle and Iris Cheung of Bereskin & Parr provide an update on the final version of guidelines issued by Canada’s federal drug price regulator—and its likely implications.
Big Pharma
Canada authorises compulsory licences for COVID-19 shortfalls
27 March 2020   Canada is the latest country to adopt emergency measures in order to secure drugs and medical equipment in the fight against COVID-19.
Americas
Pharma industry challenges Canada’s drug pricing plan
9 September 2019   Innovative Medicines Canada, an association that represents drugmakers in Canada, has challenged the overhaul of Canada’s drug-pricing regime.

More on this story

Big Pharma
Pricing, patents and the PMPRB in Canada
14 December 2020   Micheline Gravelle and Iris Cheung of Bereskin & Parr provide an update on the final version of guidelines issued by Canada’s federal drug price regulator—and its likely implications.
Big Pharma
Canada authorises compulsory licences for COVID-19 shortfalls
27 March 2020   Canada is the latest country to adopt emergency measures in order to secure drugs and medical equipment in the fight against COVID-19.
Americas
Pharma industry challenges Canada’s drug pricing plan
9 September 2019   Innovative Medicines Canada, an association that represents drugmakers in Canada, has challenged the overhaul of Canada’s drug-pricing regime.

More features

LSPN: In-house ‘chess game’ is the same, but the rules have changed
Life sciences leaders recognised at LSPN Awards USA 2025
UK-India trade deal is ‘a missed opportunity for UK pharma’, says industry body
LSPN: Counsel grapple with AI’s impact on training and critical thinking
'Nothing can stand in the way of our work': Ukraine resumes IP system
LSPN: Trump's policy storm causing chaos and confusion
Taylor Wessing expands in Europe with Paris team
LSPN: Using ‘the patentee’s friend’ in Section 112 claims